Yu.E. Less

Yu.E. Less

Auto-generated profile, based on publicly available information

Yu.E. Less

Moscow Research and Clinical Center for Neuropsychiatry

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
AGA.G. Gersamia
A.G. Gersamia
KPK.I. Pochigaeva
K.I. Pochigaeva
YLYu.E. Less
Yu.E. Less
RAR.G. Akzhigitov
R.G. Akzhigitov
AGA.B. Guekht
A.B. Guekht
Natalia V. GulyaevaNatalia V. Gulyaeva
Natalia V. Gulyaeva
Various studies have indicated that the prevalence of depression is almost twice as high among women as among men. A major factor associated with the development of depression and other affective disorders are adverse and psychologically traumatic life events that contribute to changes in the neuroendocrine system, altering the capacity to adapt to stress. These changes are involved in the pathogenesis of mental disorders, along with genetic and other factors, and are to a significant degree regulated by gender dependent mechanisms. While women have a high prevalence of depressive disorders, men show a higher rate of alcohol and substance abuse. These differences in the epidemiology are most likely explained by different predisposition to mental disorders in men and women and a diversity of biological consequences to adverse life events. Taking this into account, there is a need for a critical review of currently used approaches to modeling depressive disorders in preclinical studies, including the use of animals of both sexes. Adaptation of experimental models and protocols taking into account gender characteristics of neuroendocrine changes in response to stress, as well as structural-morphological, electrophysiological, molecular, genetic and epigenetic features, will significantly increase the translational validity of experimental work.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
APA.O. Prosvetov
A.O. Prosvetov
BTB.D. Tsygankov
B.D. Tsygankov
AGA.B. Guekht
A.B. Guekht
EKE.V. Kuznetsov
E.V. Kuznetsov
ULU.E. Less
U.E. Less
SRS.R. Rangus
S.R. Rangus
Распространенность аффективных нарушений у пациентов с болезнью Паркинсона (БП) значительно выше, чем в общей популяции у лиц того же возраста. Известно, что эффективность антидепрессантов при БП с депрессивным расстройством ниже, чем у пациентов с первичной депрессией. При депрессии, резистентной к стандартной фармакотерапии, доступны другие терапевтические стратегии. Транскраниальная магнитная стимуляция — это один из самых популярных и безопасных методов стимуляции мозга, который успешно применяется для лечения первичной депрессии. Накопление опыта использования транскраниальной магнитной стимуляции позволило расширить применение метода на другие нозологии, включая БП. В статье отражены данные литературы о применении разных протоколов транскраниальной магнитной стимуляции для лечения депрессивного расстройства у пациентов с БП.